Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 Peptide Vaccination in High-Risk Hematological Malignancies
NCT00433745Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Feb 2007
- Primary completion
- Nov 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of galinpepimut-s in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 2 more, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Toxicity and Side Effects at 16 weeks. Started Feb 2007; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00433745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433745.